Leonie Speksnijder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonie Speksnijder has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Hugo W. F. van Eijndhoven
Department of Obstetrics and Gynecology, Isala Hospital, Zwolle, The Netherlands
2 shared publications Jeroen van Bavel
Amphia Hospital, Department of Obstetrics and Gynecology, Breda, the Netherlands
2 shared publications- Kim Josephina Bernadette Notten
Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegenn, The Netherlands
2 shared publications - Kirsten B. Kluivers
Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications - Manon H. Kerkhof
Department of Gynecology and Reconstructive Pelvic Surgery, Curilion Women’s Health Clinic, Haarlem, The Netherlands
2 shared publications - Melle A. Spruijt
Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegenn, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in International Urogynecology Journal
- p. 1-9
Botulinum Toxin A Injection Versus Placebo as Treatment for Chronic Pelvic Pain: Evaluating the Influence of Patients’ Pretreatment Expectations
Introduction and Hypothesis: Chronic pelvic pain (CPP) impacts 6-27% of women aged 18-50 worldwide. To date, few studies have evaluated the influence of patients’ pretreatment expectations on treatment outcomes in this population. We hypothesize that women’s pretreatment expectations are associated with their perceived treatment outcomes. Methods: This prospective cohort study included 94 women with CPP who received either botulinum toxin A or placebo injections, both combined with pelvic floor muscle therapy. Patients’ expectations were assessed at baseline and at 26 weeks using questionnaires on pretreatment expectations, pelvic floor symptoms impact (PFIQ-7), health status (EQ-5D), and pain levels (VAS). Associations between expectations and outcomes were examined using multiple linear regression. Results: Most women (78%) reported high expectations, but these were only met in one out of five women at 26 weeks follow-up. Low expectations of improvement were associated with a poorer impression of improvement at 26 weeks ( p = 0.023). Women with high pretreatment expectations regarding their health status reported better EQ-5D health status scores at 26 weeks ( p < 0.001). Treatment allocation did not affect expectations or outcomes. The baseline severity of symptoms of the individual questionnaires significantly influenced subsequent outcomes in the analysed questionnaires, reflecting parallel symptom trajectories. Conclusions: Patients’ pretreatment expectations were associated with treatment outcomes in women with CPP. Low expectations were reflected by poorer perceived improvement at 26 weeks, providing new insights into the role of expectations in the management of CPP and trial outcomes.
- 27 July 2026
- Published by Springer Nature in International Urogynecology Journal
- p. 1-9
Open AccessBotulinum Toxin A Injection Versus Placebo as Treatment for Chronic Pelvic Pain: Evaluating the Influence of Patients’ Pretreatment Expectations
Introduction and Hypothesis: Chronic pelvic pain (CPP) impacts 6-27% of women aged 18-50 worldwide. To date, few studies have evaluated the influence of patients’ pretreatment expectations on treatment outcomes in this population. We hypothesize that women’s pretreatment expectations are associated with their perceived treatment outcomes. Methods: This prospective cohort study included 94 women with CPP who received either botulinum toxin A or placebo injections, both combined with pelvic floor muscle therapy. Patients’ expectations were assessed at baseline and at 26 weeks using questionnaires on pretreatment expectations, pelvic floor symptoms impact (PFIQ-7), health status (EQ-5D), and pain levels (VAS). Associations between expectations and outcomes were examined using multiple linear regression. Results: Most women (78%) reported high expectations, but these were only met in one out of five women at 26 weeks follow-up. Low expectations of improvement were associated with a poorer impression of improvement at 26 weeks ( p = 0.023). Women with high pretreatment expectations regarding their health status reported better EQ-5D health status scores at 26 weeks ( p < 0.001). Treatment allocation did not affect expectations or outcomes. The baseline severity of symptoms of the individual questionnaires significantly influenced subsequent outcomes in the analysed questionnaires, reflecting parallel symptom trajectories. Conclusions: Patients’ pretreatment expectations were associated with treatment outcomes in women with CPP. Low expectations were reflected by poorer perceived improvement at 26 weeks, providing new insights into the role of expectations in the management of CPP and trial outcomes.
- Open Access
- 16 July 2026
- Published by Springer Nature in International Urogynecology Journal
- p. 1-11
Botulinum Toxin A Injection Treatment in Chronic Pelvic Pain Patients: Open-Label Extension Study and 12-Month Follow-Up After RCT
Introduction and Hypothesis: A recent randomized controlled trial (RCT) demonstrated that while botulinum toxin A (BTA) significantly reduced pelvic floor muscle activity compared to placebo, it did not provide greater pain relief than placebo at 26 weeks. This study evaluates the effect of BTA combined with pelvic floor muscle therapy (PFMT) in placebo nonresponders and investigates long-term outcomes of BTA versus placebo in women with CPP. Methods: This open-label extension ( n = 27) and long-term follow-up study (initial responders n = 18 and BTA nonresponders n = 31) was conducted in the Netherlands as part of an RCT. Placebo nonresponders received 100 units of BTA injected into the pelvic floor muscles during the open-label extension study. PFMT was provided at 4, 8, 12, and 26 weeks post-injection, with validated questionnaires completed at each time point and at 12 months follow-up. Primary outcomes were average pain score (0–10) and Patient Global Impression of Improvement. Secondary outcomes included quality-of-life questionnaires and pelvic floor muscle function. Data were analysed using mixed models. Results: No serious safety concerns were observed. In placebo nonresponders, pain improved after BTA injections, with sustained improvement at 12 months. Among initial responders in the RCT, pain improvement persisted up to 12 months after both BTA and placebo treatment, with no significant difference between treatment groups. Conclusion: Our findings support the safety of BTA treatment for women with CPP. When effective, both BTA and placebo injections combined with PFMT were associated with sustained benefits for up to 1 year, although these exploratory findings should be interpreted with caution.
- 16 July 2026
- Published by Springer Nature in International Urogynecology Journal
- p. 1-11
Open AccessBotulinum Toxin A Injection Treatment in Chronic Pelvic Pain Patients: Open-Label Extension Study and 12-Month Follow-Up After RCT
Introduction and Hypothesis: A recent randomized controlled trial (RCT) demonstrated that while botulinum toxin A (BTA) significantly reduced pelvic floor muscle activity compared to placebo, it did not provide greater pain relief than placebo at 26 weeks. This study evaluates the effect of BTA combined with pelvic floor muscle therapy (PFMT) in placebo nonresponders and investigates long-term outcomes of BTA versus placebo in women with CPP. Methods: This open-label extension ( n = 27) and long-term follow-up study (initial responders n = 18 and BTA nonresponders n = 31) was conducted in the Netherlands as part of an RCT. Placebo nonresponders received 100 units of BTA injected into the pelvic floor muscles during the open-label extension study. PFMT was provided at 4, 8, 12, and 26 weeks post-injection, with validated questionnaires completed at each time point and at 12 months follow-up. Primary outcomes were average pain score (0–10) and Patient Global Impression of Improvement. Secondary outcomes included quality-of-life questionnaires and pelvic floor muscle function. Data were analysed using mixed models. Results: No serious safety concerns were observed. In placebo nonresponders, pain improved after BTA injections, with sustained improvement at 12 months. Among initial responders in the RCT, pain improvement persisted up to 12 months after both BTA and placebo treatment, with no significant difference between treatment groups. Conclusion: Our findings support the safety of BTA treatment for women with CPP. When effective, both BTA and placebo injections combined with PFMT were associated with sustained benefits for up to 1 year, although these exploratory findings should be interpreted with caution.
- 29 September 2022
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 279, 50-54
Overnight removal of urinary indwelling catheter following vaginal prolapse surgery (OVERACT)
- 29 September 2022
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 279, 50-54
Overnight removal of urinary indwelling catheter following vaginal prolapse surgery (OVERACT)
- 23 October 2020
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 58 (3) , 476-482
Which factors are associated with anal incontinence after obstetric anal sphincter injury?
Objectives: Obstetric anal sphincter injury (OASI) is an important factor in the etiology of anal incontinence. This study aimed to evaluate whether anal sphincter defects, levator avulsion or levator ballooning after OASI are associated with severity of anal incontinence. Furthermore, we evaluated whether factors such as constipation and altered stool consistency are associated with symptoms of incontinence after OASI.Methods: In this multicenter prospective observational cohort study, women with OASI were invited to participate at least 3 months after primary repair. All women completed validated questionnaires, including St Mark's incontinence score, Bristol stool scale (BSS) and Cleveland clinic constipation score (CCCS), and underwent four‐dimensional (4D) transperineal ultrasound for assessment of the levator ani muscle and anal sphincter.Results: In total, 220 women were included. Median follow‐up was 4 months (range, 3–98 months). Univariate linear regression analysis showed an association of St Mark's incontinence score with a residual defect of the external anal sphincter (EAS) (β, 1.55 (95% CI, 0.04–3.07); P = 0.045), higher parity (β, 0.85 (95% CI, 0.02–1.67); P = 0.046), BSS (β, 1.28 (95% CI, 0.67–1.89); P < 0.001) and CCCS (β, 0.36 (95% CI, 0.18–0.54); P < 0.001). However, multivariate linear regression found an association of St Mark's incontinence score only with BSS (β, 1.50 (95% CI, 0.90–2.11); P < 0.001) and CCCS (β, 0.46 (95% CI, 0.29–0.63); P < 0.001).Conclusions: Residual defects of the EAS, detected on 4D transperineal ultrasound, are associated with severity of anal incontinence symptoms measured using St Mark's incontinence score 4 months after OASI repair. Furthermore, clinical factors such as constipation and altered stool consistency appear to influence this association and may therefore play a more important role in clinical management. © 2020 International Society of Ultrasound in Obstetrics and Gynecology
- 23 October 2020
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 58 (3) , 476-482
Which factors are associated with anal incontinence after obstetric anal sphincter injury?
Objectives: Obstetric anal sphincter injury (OASI) is an important factor in the etiology of anal incontinence. This study aimed to evaluate whether anal sphincter defects, levator avulsion or levator ballooning after OASI are associated with severity of anal incontinence. Furthermore, we evaluated whether factors such as constipation and altered stool consistency are associated with symptoms of incontinence after OASI.Methods: In this multicenter prospective observational cohort study, women with OASI were invited to participate at least 3 months after primary repair. All women completed validated questionnaires, including St Mark's incontinence score, Bristol stool scale (BSS) and Cleveland clinic constipation score (CCCS), and underwent four‐dimensional (4D) transperineal ultrasound for assessment of the levator ani muscle and anal sphincter.Results: In total, 220 women were included. Median follow‐up was 4 months (range, 3–98 months). Univariate linear regression analysis showed an association of St Mark's incontinence score with a residual defect of the external anal sphincter (EAS) (β, 1.55 (95% CI, 0.04–3.07); P = 0.045), higher parity (β, 0.85 (95% CI, 0.02–1.67); P = 0.046), BSS (β, 1.28 (95% CI, 0.67–1.89); P < 0.001) and CCCS (β, 0.36 (95% CI, 0.18–0.54); P < 0.001). However, multivariate linear regression found an association of St Mark's incontinence score only with BSS (β, 1.50 (95% CI, 0.90–2.11); P < 0.001) and CCCS (β, 0.46 (95% CI, 0.29–0.63); P < 0.001).Conclusions: Residual defects of the EAS, detected on 4D transperineal ultrasound, are associated with severity of anal incontinence symptoms measured using St Mark's incontinence score 4 months after OASI repair. Furthermore, clinical factors such as constipation and altered stool consistency appear to influence this association and may therefore play a more important role in clinical management. © 2020 International Society of Ultrasound in Obstetrics and Gynecology
- Open Access
- 1 July 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 3, 100030
Three-dimensional bladder ultrasonography with the BladderScan® overestimates post void residual one week after delivery
- 1 July 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 3, 100030
Open AccessThree-dimensional bladder ultrasonography with the BladderScan® overestimates post void residual one week after delivery
- 1 January 2019
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 220 (1) , 93.e1-93.e9
Association of levator injury and urogynecological complaints in women after their first vaginal birth with and without mediolateral episiotomy
- 1 January 2019
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 220 (1) , 93.e1-93.e9
Association of levator injury and urogynecological complaints in women after their first vaginal birth with and without mediolateral episiotomy
- 30 April 2013
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 161 (6) , 1394-1400
A de novo GLI3 mutation in a patient with acrocallosal syndrome
Acrocallosal syndrome is characterized by postaxial polydactyly, macrocephaly, agenesis of the corpus callosum, and severe developmental delay. In a few patients with this disorder, a mutation in the KIF7 gene has been reported, which was associated with impaired GLI3 processing and dysregulaton of GLI3 transcription factors. A single patient with acrocallosal syndrome and a de novo p.Ala934Pro mutation in GLI3 has been reported, whereas diverse and numerous GLI3 mutations have also been described in syndromes with overlapping clinical manifestations, including Greig cephalopolysyndactyly syndrome, Pallister–Hall syndrome, trigonocephaly with craniosynostosis and polydactyly, oral–facial‐digital syndrome, and non‐syndromic polydactyly. Here, we describe a second patient with acrocallosal syndrome, who has a de novo, novel c.2786T > C mutation in GLI3, which predicts p.Leu929Pro. This mutation is in the same domain as the mutation in the previously reported patient. These data confirm that mutations in GLI3 are a cause of the acrocallosal phenotype.
- 30 April 2013
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 161 (6) , 1394-1400
A de novo GLI3 mutation in a patient with acrocallosal syndrome
Acrocallosal syndrome is characterized by postaxial polydactyly, macrocephaly, agenesis of the corpus callosum, and severe developmental delay. In a few patients with this disorder, a mutation in the KIF7 gene has been reported, which was associated with impaired GLI3 processing and dysregulaton of GLI3 transcription factors. A single patient with acrocallosal syndrome and a de novo p.Ala934Pro mutation in GLI3 has been reported, whereas diverse and numerous GLI3 mutations have also been described in syndromes with overlapping clinical manifestations, including Greig cephalopolysyndactyly syndrome, Pallister–Hall syndrome, trigonocephaly with craniosynostosis and polydactyly, oral–facial‐digital syndrome, and non‐syndromic polydactyly. Here, we describe a second patient with acrocallosal syndrome, who has a de novo, novel c.2786T > C mutation in GLI3, which predicts p.Leu929Pro. This mutation is in the same domain as the mutation in the previously reported patient. These data confirm that mutations in GLI3 are a cause of the acrocallosal phenotype.